Stem cells treatment for fistulas in Crohn’s disease is about to be approved in Catalonia a

by Fundació Clínic per a la Recerca Biomèdica

5 years ago
Stem cells, fistulas, Crohn’s disease

Treatment with mesenchymal stem cells (MSCs), extracted from fat tissue, is a powerful tool for the cure of autoimmune diseases such as Crohn’s disease.

World Inflammatory Bowel Disease Day (ulcerative colitis)

by GoodGut

5 years ago
ulcerative colitis, World Inflammatory Bowel Disease, Crohn’s disease, gastrointestinal system

Today is World Inflammatory Bowel Disease (IBD) Day; IBD is a set of chronic disorders of unknown cause affecting the gastrointestinal system in over 50 million people. The most common forms are Cr...

Takeda and TiGenix announce that Swissmedic has accepted for review the file on Cx601 for the treatment of complex perianal fistulas in Crohn’s disease patients

by TIGENIX SAU

7 years ago
Swissmedic, Crohn’s disease, Cx601, perianal fistulas

Takeda Pharma AG (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and Nasdaq: TIG) (“TiGenix”) today announced that the Swiss Agency for Therapeutic Products (Swi...

TiGenix Cx601 positive long-term results to be presented at digestive disease week

by TIGENIX SAU

7 years ago
Cx601, clinical trial, perianal fistulas, Crohn’s disease

TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop nove...

TiGenix announces positive topline week-104 data for Cx601 ADMIRE-CD Trial

by TIGENIX SAU

7 years ago
Crohn’s disease, Cx601 ADMIRE-CD study, week 104 data

TiGenix NV (Euronext Brussels and Nasdaq: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic stem ce...

Takeda and TiGenix report new data highlighting maintenance of long-term remission of complex perianal Fistulas in Crohn’s disease patients with Cx601

by TIGENIX SAU

7 years ago
Phase 3 ADMIRE-CD clinical trial, stem cells, compound Cx601, perianal fistulas, Crohn’s disease

Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and Nasdaq: TIG) (“TiGenix”) today announced new data from the Phase 3 ADMIRE-CD clinical trial, ...

TiGenix announces Orphan Drug Designation (ODD) for Cx601 in Switzerland

by TIGENIX SAU

8 years ago
Cx601, Crohn’s disease, Orphan Drug Designation

TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells...

Takeda and TiGenix Announce the Results of the Phase 3 ADMIRE-CD Trial Investigating Cx601 in the Treatment of Complex Perianal Fistulas in Patients with Crohn’s Disease

by TIGENIX SAU

8 years ago
Cx601, TiGenix, Takeda, Crohn’s Disease, ADMIRE-CD Trial, Perianal Fistulas

Takeda and TiGenix Announce Publication in The Lancet of 24-Week Results of the Phase 3 ADMIRE-CD Trial Investigating Cx601 in the Treatment of Complex Perianal Fistulas in Patients with Crohn’s Dis...

Takeda and TiGenix enter into licensing agreement for Ex-U.S. rights to Cx601 for the treatment of complex perianal fistulas in patients with crohn’s disease

by TIGENIX SAU

8 years ago
Cx601, perianal fistulas, Crohn’s disease, eASC

Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels: TIG) (“TiGenix”) today announced that the companies have entered into an exclusive ex-U.S. li...

A protein implicated in Crohn’s Disease predisposes the development of a type of lymphoma

by CIMA - Centro de Investigación Médica Aplicada

8 years ago
marginal-zone lymphomagenesis, NKX2-3, hematological tumour, Crohn’s Disease

International research directed by CIMA of the University of Navarra suggests that inhibition of NKX2-3 may be a selective therapeutic strategy in marginal-zone lymphomagenesis